Press Releases | November 9, 2016
Inmedix CEO to Co-Chair Study Group Highlighting Autonomic Nervous System (ANS) Effect on Autoimmune Disease Treatment Success at ACR/ARHP Annual Meeting 2016
Seattle, Washington (PRWEB ) November 09, 2016 -- Inmedix, the leader in heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, today announced that CEO & Co-founder, Andrew J. Holman, MD, will co-chair the ACR study group “Autonomic Neuroregulation of Autoimmune Disease” with Paul-Peter Tak, MD, PhD, Chief Immunology Officer & Senior Vice President R&D Pipeline at GlaxoSmithKline (GSK), during ACR/ARHP Annual Meeting 2016, being held November 11-16, 2016 at Walter E. Washington Convention Center, Washington DC. Also, speaking will be Carolina Kagan, MSc, regulatory scientist, reviewing pre- and post-market applications in the FDA's Center for Devices and Radiological Health (CDRH), the Office of in Vitro Diagnostics and Radiological Health (OIR) and Division of Immunology and Hematology Devices (DIHD)
Click below to read the full press release.